ErbB2 is an attractive target for immunotherapy, as it is a transmembrane tyrosine kinase receptor, overexpressed on tumour cells of different origin, with a key role in the development of malignancy (Slamon et al, 1987). The gene discussed is ERBB2; the disease is neoplasm.